214 The KRASG12D(ON) covalent tricomplex inhibitor RM-044 increases tumor antigen presentation and TCR repertoire diversity to promote anti-tumor immunity in a preclinical model of KRASG12D mutant cancer
Main Authors: | Nataliya Tovbis Shifrin, Marie Menard, Haley Courtney, Swetha Ganesh, Alice Kumamoto, Lillian Seu, Jacqueline AM Smith, Elsa Quintana |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors
by: Qi Ai, et al.
Published: (2023-05-01) -
Efficacy and Safety of KRASG12C Inhibitors in Advanced Solid Tumors with KRASG12C-mutated: A Single-arm Meta-analysis
by: TAN Dengxu, et al.
Published: (2023-07-01) -
Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis
by: Qi-An Chen, et al.
Published: (2024-02-01) -
Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models
by: Daniel J. Sisler, et al.
Published: (2023-02-01) -
The KRASG12C inhibitors in lung cancer therapy
by: Maciej Jędrak, et al.
Published: (2023-09-01)